Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 48

1.

Magnolol-mediated regulation of plasma triglyceride through affecting lipoprotein lipase activity in apolipoprotein A5 knock-in mice.

Chang CK, Lin XR, Lin YL, Fang WH, Lin SW, Chang SY, Kao JT.

PLoS One. 2018 Feb 9;13(2):e0192740. doi: 10.1371/journal.pone.0192740. eCollection 2018.

2.

Apolipoprotein A-V deficiency enhances chylomicron production in lymph fistula mice.

Zhang LS, Xu M, Yang Q, Ryan RO, Howles P, Tso P.

Am J Physiol Gastrointest Liver Physiol. 2015 Apr 1;308(7):G634-42. doi: 10.1152/ajpgi.00339.2014. Epub 2015 Jan 23.

3.

ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content.

Camporez JP, Kanda S, Petersen MC, Jornayvaz FR, Samuel VT, Bhanot S, Petersen KF, Jurczak MJ, Shulman GI.

J Lipid Res. 2015 Mar;56(3):526-36. doi: 10.1194/jlr.M054080. Epub 2014 Dec 29.

4.

Apolipoprotein A5 deficiency aggravates high-fat diet-induced obesity due to impaired central regulation of food intake.

van den Berg SA, Heemskerk MM, Geerling JJ, van Klinken JB, Schaap FG, Bijland S, Berbée JF, van Harmelen VJ, Pronk AC, Schreurs M, Havekes LM, Rensen PC, van Dijk KW.

FASEB J. 2013 Aug;27(8):3354-62. doi: 10.1096/fj.12-225367. Epub 2013 May 6.

PMID:
23650188
5.

Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation.

Shu X, Nelbach L, Ryan RO, Forte TM.

Biochim Biophys Acta. 2010 May;1801(5):605-8. doi: 10.1016/j.bbalip.2010.02.004. Epub 2010 Feb 11.

6.

ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.

Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, Havekes LM, Groen AK, van Dijk KW.

J Biol Chem. 2004 Jul 2;279(27):27941-7. Epub 2004 Apr 16.

7.

Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice.

van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije N, Wesseling JG, Groen AK, Chamuleau RA.

Biochem Biophys Res Commun. 2002 Aug 2;295(5):1156-9.

PMID:
12135615
8.

Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of apoa5 (-/-) mice.

Sharma V, Beckstead JA, Simonsen JB, Nelbach L, Watson G, Forte TM, Ryan RO.

Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):474-80. doi: 10.1161/ATVBAHA.112.301078. Epub 2013 Jan 17.

9.

Apolipoprotein A-V N-terminal domain lipid interaction properties in vitro explain the hypertriglyceridemic phenotype associated with natural truncation mutants.

Wong-Mauldin K, Raussens V, Forte TM, Ryan RO.

J Biol Chem. 2009 Nov 27;284(48):33369-76. doi: 10.1074/jbc.M109.040972. Epub 2009 Oct 13.

10.

Glucose regulates the expression of the apolipoprotein A5 gene.

Nowak M, Helleboid-Chapman A, Jakel H, Moitrot E, Rommens C, Pennacchio LA, Fruchart-Najib J, Fruchart JC.

J Mol Biol. 2008 Jul 25;380(5):789-98. doi: 10.1016/j.jmb.2008.04.057. Epub 2008 Apr 30.

PMID:
18572192
11.

Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice.

Nelbach L, Shu X, Konrad RJ, Ryan RO, Forte TM.

J Lipid Res. 2008 Mar;49(3):572-80. Epub 2007 Dec 3.

12.

Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review.

Talmud PJ.

Atherosclerosis. 2007 Oct;194(2):287-92. Epub 2007 Jan 12. Review.

PMID:
17222847
13.

Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?

Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC.

Ann Med. 2006;38(1):2-10. Review.

PMID:
16448983
14.

Altered apolipoprotein A-V expression during the acute phase response is independent of plasma triglyceride levels in mice and humans.

Becker S, Schomburg L, Renko K, Tölle M, van der Giet M, Tietge UJ.

Biochem Biophys Res Commun. 2006 Jan 20;339(3):833-9. Epub 2005 Nov 28.

PMID:
16325772
15.

Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase.

Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J.

J Biol Chem. 2005 Jun 3;280(22):21553-60. Epub 2005 Mar 17.

16.

Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL.

Khovidhunkit W, Duchateau PN, Medzihradszky KF, Moser AH, Naya-Vigne J, Shigenaga JK, Kane JP, Grunfeld C, Feingold KR.

Atherosclerosis. 2004 Sep;176(1):37-44.

PMID:
15306172
17.

Liver X receptors (LXRs) regulate apolipoprotein AIV-implications of the antiatherosclerotic effect of LXR agonists.

Liang Y, Jiang XC, Liu R, Liang G, Beyer TP, Gao H, Ryan TP, Dan Li S, Eacho PI, Cao G.

Mol Endocrinol. 2004 Aug;18(8):2000-10. Epub 2004 May 6.

PMID:
15131258
18.

Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice.

Pennacchio LA, Rubin EM.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):529-34. Epub 2002 Dec 26. Review.

19.

Brown adipose tissue activity controls triglyceride clearance.

Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG, Tromsdorf UI, Weller H, Waurisch C, Eychmüller A, Gordts PL, Rinninger F, Bruegelmann K, Freund B, Nielsen P, Merkel M, Heeren J.

Nat Med. 2011 Feb;17(2):200-5. doi: 10.1038/nm.2297. Epub 2011 Jan 23.

PMID:
21258337
20.

Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.

Shu X, Nelbach L, Weinstein MM, Burgess BL, Beckstead JA, Young SG, Ryan RO, Forte TM.

Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2504-9. doi: 10.1161/ATVBAHA.110.210815. Epub 2010 Oct 21.

Supplemental Content

Support Center